Kitov Pharmaceuticals

Apr 13, 2018

TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research

Mar 08, 2018

TyrNovo to Present at BIO-Europe Spring® 2018 Conference

Mar 05, 2018

Kitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders

Dec 14, 2017

Kitov Announces Consensi(TM) as Brand Name for KIT-302

Nov 01, 2017

Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package

Oct 26, 2017

Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function

Oct 02, 2017

Kitov Announces Filing by FDA of New Drug Application for KIT-302

Jul 31, 2017

Kitov Submits New Drug Application to FDA for KIT-302

Jul 11, 2017

Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering